2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119557
    Buthiazide 2043-38-1 98.87%
    Buthiazide (Butizide) is a diuretic compound that can be used for high blood pressure research.
    Buthiazide
  • HY-119680
    AT-1459 294658-50-7 98%
    AT-1459 is a selective and orally active direct Thrombin inhibitor with a Ki value of 4.9 nM. AT-1459 exhibits excellent antithrombotic activity in both rat models of venous and arterial thrombosis. AT-1459 can be used for research on thrombosis-related diseases.
    AT-1459
  • HY-119735
    Curcolone 17015-43-9 98%
    Curcolone is a sesquiterpenoid that inhibits collagen-induced or arachidonic acid (AA)-induced platelet aggregation.
    Curcolone
  • HY-119747
    WAY-123223 137941-92-5 98%
    WAY-123223 (Compound 12) is an orally active potassium channel blocker. WAY-123223 increases the ventricular fibrillation threshold, restores sinus rhythm in ventricular fibrillation, and exerts an antiarrhythmic effect in canine models. WAY-123223 can be used in research on cardiovascular diseases such as arrhythmias.
    WAY-123223
  • HY-119762
    Spizofurone 72492-12-7 98%
    Spizofurone is an anti-ulcer compound with increased gastric mucosal blood flow activity and oral activity. Spizofurone has a similar mechanism of action to PGE2 (HY-101952), Spizofurone is capable of acting through local and systemic pathways and may promote ulcer healing by improving blood supply to the gastric mucosa. Spizofurone can be used to study the development strategy of gastric ulcer.
    Spizofurone
  • HY-119844
    Anidoxime 34297-34-2 98%
    Anidoxime is an oral activity analgesic agent.
    Anidoxime
  • HY-119860
    Ataprost 83997-19-7 98%
    Ataprost (ONO 41483) is an orally active Carboprostacyclin (HY-112322) analogue. Ataprost exhibits 2.6 times more active than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Ataprost has the ability to relieve coronary spasm.
    Ataprost
  • HY-119873
    Celiprolol 56980-93-9 98%
    Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure.
    Celiprolol
  • HY-119890
    Isbogrel 89667-40-3 98%
    Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID50 value of 0.04 mg/kg.
    Isbogrel
  • HY-119961
    (+)-Mepivacaine 24358-84-7 99.72%
    (+)-Mepivacaine is a racemic isomer of Mepivacaine (HY-B0517), which has analgesic and vasoconstrictive activity. Mepivacaine is an amide type agent that temporarily causes local loss of consciousness. Mepivacaine binds to specific voltage-gated sodium channels on neuronal cell membranes, inhibiting sodium influx and membrane depolarization.
    (+)-Mepivacaine
  • HY-119995
    Chloropyramine 59-32-5 98%
    Chloropyramine is competitive reversible H1 receptor antagonist. Chloropyramine also has anti-tumour activity in breast cancer. Chloropyramine can be used for the research of allergic conditions, such as conjunctivitis and bronchial asthma.
    Chloropyramine
  • HY-120134
    BMS 183920 153072-33-4 98%
    BMS 183920 is a diacidic and potent angiotensin II receptor antagonist, with a Ki value of 2.9 nM in the rat adrenal cortex binding assay and a KB value of 0.061 nM in the rabbit aorta functional assay. BMS 183920 can be used for research of antihypertensive.
    BMS 183920
  • HY-120147
    Ethiazide 1824-58-4 98%
    Ethiazide is a thiazole diuretic which inhibits renal reabsorption of sodium and water, thereby increasing urine excretion, reducing fluid retention, and lowering blood volume and blood pressure. Ethiazide can be used for cardiovascular research.
    Ethiazide
  • HY-120200
    YF-452 1951466-83-3 98%
    YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research.
    YF-452
  • HY-120257
    IDN-1965 204919-14-2 98%
    IDN-1965 is an irreversible, broad-spectrum caspase inhibitor. IDN-1965 prevents downstream apoptotic events (such as DNase activation) and significantly delays cytochrome c release by inhibiting caspase activity. IDN-1965 significantly delayed death in mice with cardiomyocyte apoptosis. IDN-1965 completely prevents left ventricular dilation, systolic dysfunction, and fibrosis in mice with dilated cardiomyopathy. IDN-1965 can be used to study apoptosis-related diseases such as heart failure and the mechanisms of apoptosis initiation.
    IDN-1965
  • HY-120267
    TID43 19231-60-8 98%
    TID43 is a CK2 inhibitor, with an IC50 of 0.3 μM. TID43 can be used for anti-angiogenic research.
    TID43
  • HY-120309
    BMY 42393 136451-58-6 98%
    BMY 42393 is an orally active prostacyclin agonist which suppresses monocyte-macrophage atherogenic activity and cytokine production. BMY 42393 can be used for atherosclerosis research.
    BMY 42393
  • HY-120325
    DHMPA 18684-28-1 98%
    DHMPA is an effective depletor of norepinephrine content of the heart, brain and spleen in mouse and rat. DHMPA has antihypertensive effects.
    DHMPA
  • HY-120355
    AP14145 1446770-54-2 98%
    AP14145 is an inhibitor for small conductance calcium-activated potassium channel, inhibits KCa2.2 channel and KCa channel with IC50 of 1.1 μM and 1.1 μM. AP14145 prolongs atrial effective refractory period (AERP) in rats, causes the conversion of atrial fibrillation to sinus rhythum in porcine left ventricular dysfunction models, and exhibits antiarrhythmic effect.
    AP14145
  • HY-120375
    LUF7346 1821638-40-7 98%
    LUF7346 is a potent Kv11.1 (hERG) channel negative allosteric modulator, with an IC50 of 35.6 ± 3.2 nM.
    LUF7346
Cat. No. Product Name / Synonyms Application Reactivity